grant
Drug concentration measurement for HIV prevention targets: toward a population-based HIV impact assessment (PHIA) for PrEP
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 15 Feb 2024Deadline 31 Dec 2028
NIHUS FederalResearch GrantFY202621+ years oldAIDS VirusAIDS preventionAIDS testAIDS/HIVAIDS/HIV testAchievementAchievement AttainmentAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAdherenceAdoptedAdultAdult HumanAdvocateAfrica South of the SaharaAgeAnti-viral AgentsAutomobile DrivingBehavioralBioethicsBiomedical EthicsBlood PlasmaBlood SampleBlood specimenCause of DeathConcentration measurementCountryDataDevelopmentDiagnosisDrugsEpidemicFemale AdolescentsFormulationGeneral PopulationGeneral PublicGoalsGovernmentGuidelinesHIVHIV InfectionsHIV PreventionHIV SeronegativitiesHIV SeronegativityHIV disease statusHIV disease transmissionHIV incidenceHIV individualsHIV infected individualsHIV infected personsHIV infection spreadHIV infection statusHIV infection transmissionHIV interventionHIV negativeHIV peopleHIV positive individualsHIV positive peopleHIV riskHIV serostatusHIV spreadHIV statusHIV testHIV therapeuticHIV therapyHIV transmissionHIV treatmentHIV viral infectionHIV viral transmissionHIV virus infectionHIV-1 incidenceHIV-1 infectionHIV-1 infection incidenceHIV-1 interventionHIV-1 preventionHIV-1 spreadHIV-1 testHIV-1 therapeuticHIV-1 therapyHIV-1 transmissionHIV-1 treatmentHIV-1 virus transmissionHIV-2 testHIV/AIDSHIV/AIDS incidenceHIV/AIDS preventionHIV/AIDS transmissionHIV1 infection statusHIV1 statusHTLV-III SeronegativitiesHTLV-III SeronegativityHeterosexualsHomeHuman Immunodeficiency Virus Type 1 transmissionHuman Immunodeficiency Virus therapyHuman Immunodeficiency Virus treatmentHuman Immunodeficiency VirusesHuman immunodeficiency virus testIncidenceIndividualInfection by HIV-1Infection from HIV-1Infection of HIV-1International AgenciesInterruptionInvestigatorsKenyaKidney Function TestsLAV-HTLV-IIILicensureLymphadenopathy-Associated VirusMSMMan who have sex with ManMapsMeasurementMeasuresMedicationMethodsModelingMonitorObservational StudyOralPLWHPWHParticipantPersonsPharmaceutical PreparationsPlacebosPlasmaPlasma SerumPolicy MakerPopulationPopulation GroupPopulation SurveillancePrEPPrevent HIVPublic Health SurveillanceReportingResearchResearch PersonnelResearchersReticuloendothelial System, Serum, PlasmaRiskRisk BehaviorsRisk ReductionRisky BehaviorScientific Advances and AccomplishmentsScientistSeriesSham TreatmentSouth AfricaStudy modelsSub-Saharan AfricaSubsaharan AfricaSurvey InstrumentSurveysSustainable DevelopmentTimeTransmissionViralViral BurdenViral LoadViral Load resultVirus-HIVWomanWorld Health Organizationactive controladolescent girladulthoodagesanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsat risk behaviorcivil societycohortcommunity advisory boardcommunity advisory committeecommunity advisory panelcomparativecost effectivedesigndesigningdevelopmentaldrivingdrug/agentexperiencehomeshuman immunodeficiency virus incidencehuman immunodeficiency virus infectionhuman immunodeficiency virus transmissionimplementation studyindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinfected with HIVinfected with human immunodeficiency virusinnovateinnovationinnovativeinterestmarkov modelmeetingmeetingsmen having sex with menmen who have sex with menmen who have sex with other menmethods to study multiple-level influencesmortalitymulti-level analysismulti-level modelmultilevel analysismultilevel modelmultilevel modelingobservational research studyobservational surveypeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspharmacologicpopulation basedpre-exposure prophylaxispreferenceprevent AIDSprevent human immunodeficiency virusprogramsreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrisk-reducingscale upscientific accomplishmentsscientific advancesself testingseroconversionsham therapysocial stigmaspread of human immunodeficiency virusstigmatransmission processtreat HIVtreat Human Immunodeficiency Virusyoung woman
Description preview
Sub-Saharan Africa (SSA) is home to two-thirds of all people living with HIV (PLHIV). Widely-adopted targets
such as “95-95-95” (diagnosing ≥95% of PLHIV, treating ≥95% of those diagnosed, and achieving viral load
suppression in ≥95% of those on treatment) have fueled tremendous progress in access and effective use of
HIV treatment, with…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click